ReviewInternational journal of molecular sciences2023
DHA/EPA (Omega-3) and LA/GLA (Omega-6) as Bioactive Molecules in Neurodegenerative Diseases.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Metabolomic insights into late-life depression: a systematic review.BMC geriatrics · 2025Pooled it
- Metabolic profile association with white matter hyperintensity in patients with mild cognitive impairment.IBRO neuroscience reports · 2026Article
- Gut microbiota as a modulator of HDAC: insights into Alzheimer's disease treatment.Pharmacological reports : PR · 2026Review
- Dietary supplementation with Acer truncatum seed modulates lipid profiles and enriches unsaturated fatty acids in egg yolk of laying hens.Poultry science · 2026Article
- Determining the metabolic profile measured using ultra-high pressure liquid chromatography associated with Beta Amyloid burden in the brain in individuals with mild cognitive impairment.Research square · 2026Article
- Towards Microalgal Biorefinery: Multiproduct Fractionation ofMarine drugs · 2026Article
- Research Progress on the Anti-Inflammatory and Antioxidant Effects of Daidzein: Its Mechanisms of Action in Related Diseases, and Related Nanoformulations to Enhance Its Bioavailability.Antioxidants (Basel, Switzerland) · 2026Review
- Octanoic acid treatment alleviates cold-induced depression-like behaviors via targeting the AKR1B1-PGF2α pathway.iScience · 2026Article
- Lipid metabolism and neurodegeneration: Mechanistic insights and therapeutic targets.Ageing research reviews · 2026Review
- Radiomics: Current Applications and Future Directions.MedComm · 2026Review
- Multi-omics analysis of glutamine and fish collagen peptides in alleviating post-antibioticExperimental and therapeutic medicine · 2026Article
- Synergistic Neuroprotection of MFSD2A Overexpression and DHA Supplementation in Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2026Article
- Safety of Commercial Cod Products and Potential Impact on Consumers.Foods (Basel, Switzerland) · 2026Article
- Targeting risk factors and strategies for prevention of peripheral neuropathy: focus on B-vitamin deficiencies and metabolic diseases.Neurological research and practice · 2026Review
- Docosahexaenoic Acid Attenuates Visceral Pain by Suppressing Spinal CXCL10/CXCR3/ERK Signaling.Nutrients · 2026Article
- Comprehensive Profiling of Triglycerides in Wild Eastern MediterraneanMolecules (Basel, Switzerland) · 2026Article
- The impact of rumen and hindgut microbiomes on the persistent productivity of long-lived dairy cows.Microbiome · 2026Article
- Anticancer, Antitumor, and Antioxidant Microbial Lipids: Mechanism of Action, Production, and Clinical Application.Oxidative medicine and cellular longevity · 2026Review
- Article
- Crossroads of well-being: oral health, neurology, neuronutrition and healthy aging.Open medicine (Warsaw, Poland) · 2026Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases are characterized by neuroinflammation, neuronal depletion and oxidative stress. They coincide with subtle chronic or flaring inflammation, sometimes escalating with infiltrations of the immune system cells in the inflamed parts causing mild to severe or even lethal damage. Thus, neurodegenerative diseases show all features of autoimmune diseases. Prevalence of neurodegenerative diseases has dramatically increased in recent decades and unfortunately, the therapeutic efficacy and safety profile of available drugs is moderate. The beneficial effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) polyunsaturated fatty acids (omega-3 PUFAs) are nowadays highlighted by a plethora of studies. They play a role in suppression of inflammation, gene expression, cellular membrane fluidity/permeability, immune functionality and intracellular/exocellular signaling. The role of omega-6 polyunsaturated fatty acids, such as linoleic acid (LA), gamma linolenic acid (GLA), and arachidonic acid (AA), on neuroprotection is controversial, as some of these agents, specifically AA, are proinflammatory, whilst current data suggest that they may have neuroprotective properties as well. This review provides an overview of the existing recent clinical studies with respect to the role of omega-3 and omega-6 PUFAs as therapeutic agents in chronic, inflammatory, autoimmune neurodegenerative diseases as well as the dosages and the period used for testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.